Results 51 to 55 of about 263 (55)

Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir. [PDF]

Clin Infect Dis
Papanicolaou GA, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, Peggs KS, Solano C, Young JH, Fournier M, Murray RA, Wu J, Winston DJ, AURORA Trial Investigators.   +13 more
europepmc   +1 more source

Maribavir: Mechanism of action, clinical, and translational science. [PDF]

Clin Transl Sci
Sun K, Fournier M, Sundberg AK, Song IH.
europepmc   +1 more source

Drug-Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians. [PDF]

Clin Pharmacokinet
Burger DM, Nijboer L, Ghobreyal M, Maertens J, Blijlevens N, Hilbrands L, Baas MC, Ljungman P, Brüggemann RJM.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

5,6‐Dichlororibofuranosylbenzimidazole Inhibits the Rate of Transcription Initiation in Intact Chironomus Cells

European Journal of Biochemistry, 1982
The effect of nucleoside analogue 5.6‐dichloro‐l‐β‐D‐ribofuranosylbenzimidazole on RNA transcription has been reinvestigated after the observation that explanted salivary gland cells of Chironomus tentans efficiently take up of exogeneous ATP in an undegraded form.
E, Egyházi, A, Pigon, L, Rydlander
openaire   +2 more sources

Unmetabolized 5,6‐Dichlororibofuranosylbenzimidazole Rather than Its Monophosphate Metabolites Is Probably the Active Transcription Inhibitor

European Journal of Biochemistry, 1983
The question of whether or not the monophosphate metabolites DRB2′P and DRB5′P of the transcription inhibitor 5,6‐dichloro‐1‐β‐d‐ribofuranosylbenzimidazole (DRB) constitute the active form of the inhibitor was investigated in intact salivary gland cells of Chironomus tentants.
E, Egyházi, M, Holst, U, Tayip
openaire   +2 more sources